Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 60
Healthy Volunteers: f
View:
• Patients of both sexes with positive slit skin smear for m.leprae .
Locations
Other Locations
Egypt
Qina University hospital, South Valley University Hospital
RECRUITING
Qina
Contact Information
Primary
Lydia Atef Nassief, MSc
lydiaatef67@gmail.com
+201289416276
Backup
Eisa Mohammed Hegazy, Assist. Prof
eisa_mohamed4152@med.svu.edu.eg
+201094337795
Time Frame
Start Date: 2024-12-20
Estimated Completion Date: 2025-12-20
Participants
Target number of participants: 50
Treatments
Active_comparator: Group A: Leprosy Patients
About 40 patients suffering from Leprosy and will treated by Multi drug therapy as ( dapsone \_ clofazimine \_ rifampcin) then to assess the role of Rab 32 gene.by taking Two millimetres of venous blood from each participant At the end of third month therapy.
Active_comparator: Group B: Healthy People
About 10 Healthy People. no drugs used and then to assess the role of Rab 32 gene.by taking Two millimetres of venous blood from each participant
Related Therapeutic Areas
Sponsors
Leads: South Valley University